Compare Eli Lilly And Co (LLY) vs Alliant Energy Corporation (LNT) Price & Performance

Eli Lilly (LLY) trades at $1,179.09, up 0.76% today, with a neutral technical signal but bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations. Revenue grew to $65.18B in 2025, and net income surged to $20.64B, reflecting robust profitability. Recent news highlights LLY's acquisition of AtaiBeckley for up to $3.8B to expand its neuroscience pipeline, signaling strategic growth initiatives.

LLY's outlook remains positive driven by earnings momentum and strategic acquisitions, but high valuation multiples (P/E 41.89) and increasing debt levels pose risks. Analyst consensus is strongly bullish with a $1,380 price target, though investors should monitor execution of new deals and competitive pressures in the pharma sector.

LNT trades at $74.82, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $78.50. The company reported strong Q1 2026 earnings of $0.82 per share, beating estimates, and maintains a solid net income margin of 18.58%. Recent news highlights its $13.4 billion clean energy investment plan targeting 5-7% annual earnings growth, supported by rising data center demand.

The outlook for LNT is positive, driven by strategic capital investments and regulatory support for renewable energy. Key risks include high debt levels, with a debt-to-asset ratio rising to 48.48% in 2025, and exposure to interest rate fluctuations. Analyst sentiment is bullish with no sell ratings, but investors should monitor execution of the large capex plan and competitive pressures in the utility sector.